ZURICH (Reuters) – Roche’s newly acquired subsidiary TIB Molbiol has developed three new tests kits to detect mutations present in the new COVID-19 Omicron variant, Roche said on Friday.
“The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour,” Thomas Schinecker, head of Roche Diagnostics, said in a statement.
Roche acquired Berlin-based TIB Molbiol on Dec. 1 to expand its PCR-test portfolio to combat new infectious diseases.
(Reporting by Brenna Hughes Neghaiwi; Editing by Paul Carrel)
